Cempra, Inc. (CEMP) Stake Lowered by Wells Fargo & Company MN

Wells Fargo & Company MN reduced its position in Cempra, Inc. (NASDAQ:CEMP) by 26.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 62,272 shares of the biotechnology company’s stock after selling 22,954 shares during the period. Wells Fargo & Company MN owned about 0.12% of Cempra worth $233,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the company. State Street Corp raised its position in shares of Cempra by 85.8% in the fourth quarter. State Street Corp now owns 2,133,275 shares of the biotechnology company’s stock valued at $5,973,000 after buying an additional 985,427 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of Cempra during the fourth quarter valued at about $1,711,000. Norges Bank purchased a new position in shares of Cempra during the fourth quarter valued at about $743,000. Guggenheim Capital LLC purchased a new position in shares of Cempra during the fourth quarter valued at about $560,000. Finally, Acadian Asset Management LLC purchased a new position in shares of Cempra during the first quarter valued at about $484,000. Institutional investors and hedge funds own 49.32% of the company’s stock.

Cempra, Inc. (NASDAQ:CEMP) opened at 4.10 on Friday. The firm’s market cap is $215.26 million. Cempra, Inc. has a 12-month low of $2.55 and a 12-month high of $26.95. The firm’s 50-day moving average price is $4.20 and its 200 day moving average price is $3.77.

Cempra (NASDAQ:CEMP) last issued its quarterly earnings results on Friday, April 28th. The biotechnology company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.16. The company had revenue of $4.87 million for the quarter, compared to analyst estimates of $3.55 million. Cempra had a negative net margin of 551.45% and a negative return on equity of 56.60%. During the same quarter in the previous year, the business earned ($0.61) earnings per share. Analysts forecast that Cempra, Inc. will post ($1.06) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was first posted by BBNS and is owned by of BBNS. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://baseballnewssource.com/markets/cempra-inc-cemp-stake-lowered-by-wells-fargo-company-mn/1242312.html.

Several equities analysts recently issued reports on the company. Robert W. Baird restated an “underperform” rating on shares of Cempra in a research note on Tuesday, March 28th. Vetr lowered Cempra from a “hold” rating to a “sell” rating and set a $4.07 price target on the stock. in a research note on Monday, March 27th. Gabelli lowered Cempra from a “hold” rating to a “sell” rating in a research note on Wednesday, March 29th. Zacks Investment Research upgraded Cempra from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research note on Tuesday, May 2nd. Finally, ValuEngine lowered Cempra from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Four equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $11.34.

Cempra Company Profile

Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).

Want to see what other hedge funds are holding CEMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cempra, Inc. (NASDAQ:CEMP).

Institutional Ownership by Quarter for Cempra (NASDAQ:CEMP)

Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Veteran Pitcher Bartolo Colon Considering Retirement
Veteran Pitcher Bartolo Colon Considering Retirement
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Tigers Would Include Cash in Verlander Deal and Other MLB Trade Rumors
Todd Frazier Trade to Boston Appears to Be Decided
Todd Frazier Trade to Boston Appears to Be Decided
Chicago White Sox Continue Rebuild Without Jose Quintana
Chicago White Sox Continue Rebuild Without Jose Quintana
Mike Trout Returns from Injury With Single and Stole Base
Mike Trout Returns from Injury With Single and Stole Base


Leave a Reply

 
© 2006-2017 BBNS.